These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29145703)

  • 1. Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
    Taki Y; Imai N; Shibagaki Y
    Nephrology (Carlton); 2017 Dec; 22(12):1037-1038. PubMed ID: 29145703
    [No Abstract]   [Full Text] [Related]  

  • 2. Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
    Fukushima T; Horike H; Fujiki S; Kitada S; Sasaki T; Kashihara N
    Ther Apher Dial; 2009 Jun; 13(3):213-9. PubMed ID: 19527468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.
    Koncicki HM; Fishbane S
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1173-1175. PubMed ID: 28522653
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 8. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
    Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
    G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study.
    Schaefer F; Hoppe B; Jungraithmayr T; Klaus G; Pape L; Farouk M; Addison J; Manamley N; Vondrak K
    Pediatr Nephrol; 2016 Mar; 31(3):443-53. PubMed ID: 26482252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin variability in dialysis patients.
    Brimble KS; Clase CM
    J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 14. [Feasibility strategy of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit].
    Rottembourg JB; Dansaert A
    Nephrol Ther; 2011 Dec; 7(7):549-57. PubMed ID: 21622039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between resistance to erythropoiesis-stimulating agents and carnitine profile in patients on maintenance haemodialysis.
    Kamei D; Tsuchiya K; Nitta K; Mineshima M; Akiba T
    Nephrology (Carlton); 2018 Aug; 23(8):737-743. PubMed ID: 28608940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
    Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
    Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.